Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 253 of the 258 references it cites were found in a registry or an index; 121 of the 229 sources its claims cite were checked for support.

The use of neuroimaging techniques in the early and differential diagnosis of dementia

Open access
Chouliaras, Leonidas, O’Brien, John T. · 2023 · Molecular Psychiatry

Abstract

Abstract Dementia is a leading cause of disability and death worldwide. At present there is no disease modifying treatment for any of the most common types of dementia such as Alzheimer’s disease (AD), Vascular dementia, Lewy Body Dementia (LBD) and Frontotemporal dementia (FTD). Early and accurate diagnosis of dementia subtype is critical to improving clinical care and developing better treatments. Structural and molecular imaging has contributed to a better understanding of the pathophysiology of neurodegenerative dementias and is increasingly being adopted into clinical practice for early and accurate diagnosis. In this review we summarise the contribution imaging has made with particular focus on multimodal magnetic resonance imaging (MRI) and positron emission tomography imaging (PET). Structural MRI is widely used in clinical practice and can help exclude reversible causes of memory problems but has relatively low sensitivity for the early and differential diagnosis of dementia subtypes. 18 F-fluorodeoxyglucose PET has high sensitivity and specificity for AD and FTD, while PET with ligands for amyloid and tau can improve the differential diagnosis of AD and non-AD dementias, including recognition at prodromal stages. Dopaminergic imaging can assist with the diagnosis of LBD. The lack of a validated tracer for α-synuclein or TAR DNA-binding protein 43 (TDP-43) imaging remain notable gaps, though work is ongoing. Emerging PET tracers such as 11 C-UCB-J for synaptic imaging may be sensitive early markers but overall larger longitudinal multi-centre cross diagnostic imaging studies are needed.

Overview

CoChat Summary

## TL;DR

This review argues that neuroimaging is now central to the early and differential diagnosis of dementia, with MRI and PET providing complementary information about structure, metabolism, pathology, and prognosis. It concludes that structural MRI is widely used but relatively insensitive early on, while FDG-PET, amyloid/tau PET, and dopaminergic imaging offer stronger diagnostic value for specific dementia subtypes.

## Key findings

  • Structural MRI can help exclude alternative causes and support subtype diagnosis, but the paper says its role is mainly to corroborate a clinical syndrome and that volumetric MRI has “relatively low sensitivity” for early and differential diagnosis.
  • Reported diagnostic performances include:
  • Atrophy maps: 90% sensitivity / 84% specificity for AD, 78.7% / 98.8% for LBD, and 84.4% / 93.8% for FTD.
  • A study with 504 individuals reported MRI accuracy of 70.6% overall; VaD sensitivity 96%, controls 82%, AD 74%, and DLB only 24% sensitivity.
  • FDG-PET meta-analytic performance for AD vs controls was 90% sensitivity / 89% specificity; for AD vs non-AD dementias, a systematic review found median sensitivity 0.89 and specificity 0.74.
  • For dementia subtypes:
  • FDG-PET in DLB showed 74% sensitivity / 70% specificity in larger studies, and the “cingulate island” sign was noted as a supportive feature.
  • FP-CIT SPECT differentiated DLB from AD with 78% sensitivity / 91% specificity; in 144 MCI patients, it was 76% accurate for probable MCI-DLB.
  • Amyloid PET was reported as more sensitive than FDG-PET for AD vs FTD (89% vs 73%) but less specific (83% vs 98%).
  • Tau PET in a multicentre study of 719 participants had 89.9% sensitivity / 90.6% specificity for AD vs non-AD neurodegenerative disorders, with AUC 0.92–0.95.
  • The review highlights emerging markers such as 11C-UCB-J synaptic PET and advanced MRI methods, but says these still need larger, longitudinal, multicentre validation.

## Methods

  • Narrative review of diagnostic brain imaging in dementia, focusing on structural MRI, DTI/NODDI, perfusion MRI/ASL, fMRI, FDG-PET, amyloid PET, tau PET, dopaminergic imaging, and other PET ligands.
  • Synthesizes evidence from studies spanning AD, DLB/LBD, FTD, VaD, MCI, and control groups; several cited studies include sample sizes such as 504, 571 + 551 + 212 + 125 + 271, 719, and 1431 participants.
  • Main analysis is qualitative comparison of reported diagnostic accuracy, subtype patterns, and prognostic value across imaging modalities, with emphasis on sensitivity, specificity, and AUC where available.

## Limitations

  • The paper states that many methods still need larger, longitudinal, multicentre cross-diagnostic studies before routine clinical translation.
  • It notes that several approaches have modest or inconsistent performance in early disease: volumetric MRI has low sensitivity in prodromal stages, ASL and fMRI show overlap across groups, and FDG-PET is not recommended for clinical use at the MCI stage because of variable sensitivity/specificity.
  • Evident from the text: much of the evidence comes from single-site, highly selected research cohorts, and the paper explicitly warns that reported sensitivities/specificities are likely overestimated relative to real-world practice.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41380-023-02215-8

Cites

253 of 253 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Representative MRI scans in different types of dementia. The figure shows representative MRI scans from a non-demented control and from patients with Dementia with Lewy Bodies (DLB), Alzheimer’s disease (AD) and frontotemporal lobe degeneration (FTLD). It highlights the characteristic patterns of atrophy with relative preservation of the hippocampus in DLB, severe hippocampal atrophy in AD and temporal pole atrophy in FTLD. These scans are from the Neuroimaging of Inflammation in Memory and Other disorders (NIMROD) study cohort. Images are courtesy of Dr Elijah Mak, University of Cambridge, UK.
Fig. 1 Representative MRI scans in different types of dementia. The figure shows representative MRI scans from a non-demented control and from patients with Dementia with Lewy Bodies (DLB), Alzheimer’s disease (AD) and frontotemporal lobe degeneration (FTLD). It highlights the characteristic patterns of atrophy with relative preservation of the hippocampus in DLB, severe hippocampal atrophy in AD and temporal pole atrophy in FTLD. These scans are from the Neuroimaging of Inflammation in Memory and Other disorders (NIMROD) study cohort. Images are courtesy of Dr Elijah Mak, University of Cambridge, UK.CC BY · PubMed Central
Fig. 2 18F-Fluorodeoxyglucose (FDG) PET in Alzheimer’s disease (AD) and Dementia with Lewy Bodies (DLB). FDG PET representative images showing reduced local cerebral metabolic rate of glucose consumption in cases of AD and DLB compared to a non-demented control study participant. The white arrows highlight the relative preservation of the hippocampus and posterior cingulate gyrus in DLB compared to AD and the occipital hypometabolism in DLB. These are FDG PET scans from the Study of the clinical utility, patient preference and cost benefit of SPECT and PET-CT brain imaging in the evaluation and diagnosis of Alzheimer’s Disease (Suspected-AD). Images are courtesy of Dr Michael Firbank, Newcastle University, UK.
Fig. 2 18F-Fluorodeoxyglucose (FDG) PET in Alzheimer’s disease (AD) and Dementia with Lewy Bodies (DLB). FDG PET representative images showing reduced local cerebral metabolic rate of glucose consumption in cases of AD and DLB compared to a non-demented control study participant. The white arrows highlight the relative preservation of the hippocampus and posterior cingulate gyrus in DLB compared to AD and the occipital hypometabolism in DLB. These are FDG PET scans from the Study of the clinical utility, patient preference and cost benefit of SPECT and PET-CT brain imaging in the evaluation and diagnosis of Alzheimer’s Disease (Suspected-AD). Images are courtesy of Dr Michael Firbank, Newcastle University, UK.CC BY · PubMed Central
Fig. 3 Tau Positron emission tomography in Mild Cognitive Impairment (MCI) and Alzheimer’s Disease (AD). The figure shows the stereotypical progression of tau binding on 18F-flortaucipir from normal controls (CON) to MCI to AD depicting volume and surface in the left and right panels respectively. These are group-averaged mean maps from the NIMROD study cohort. The top of the coloured bar (red) signifies greater radioligand binding and the bottom of the bar (blue/grey) lower binding. Images are courtesy of Dr Elijah Mak, University of Cambridge, UK.
Fig. 3 Tau Positron emission tomography in Mild Cognitive Impairment (MCI) and Alzheimer’s Disease (AD). The figure shows the stereotypical progression of tau binding on 18F-flortaucipir from normal controls (CON) to MCI to AD depicting volume and surface in the left and right panels respectively. These are group-averaged mean maps from the NIMROD study cohort. The top of the coloured bar (red) signifies greater radioligand binding and the bottom of the bar (blue/grey) lower binding. Images are courtesy of Dr Elijah Mak, University of Cambridge, UK.CC BY · PubMed Central
Fig. 4 Synaptic PET imaging in different types of dementia. 11C-UCBJ PET cases images showing differential loss of synaptic density in cases of people with Alzheimer’s disease (AD), Dementia with Lewy Bodies (DLB), Progressive supranuclear palsy (PSP) and Frontotemporal dementia (FTD) compared to a healthy control. Images are courtesy of Dr Maura Malpetti and Dr Simon Jones, University of Cambridge, UK.
Fig. 4 Synaptic PET imaging in different types of dementia. 11C-UCBJ PET cases images showing differential loss of synaptic density in cases of people with Alzheimer’s disease (AD), Dementia with Lewy Bodies (DLB), Progressive supranuclear palsy (PSP) and Frontotemporal dementia (FTD) compared to a healthy control. Images are courtesy of Dr Maura Malpetti and Dr Simon Jones, University of Cambridge, UK.CC BY · PubMed Central

Verification

Claims the paper makes

88 Valid · 4 Not valid · 46 Not checked · 12 Own results and interpretations

82 more claims · 50 with their cited sources checked

Create a free account to see all 150 claims and to verify the 42 references still open.

See all claims — free account
  • It may state two separate claims as one. 60
  • Probably not a substantial claim. 8

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

1 of 1

Cited works that were retracted

Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.

1 of 1

Citations

Cites

1 retracted

Show all 258 references

Cited by

See all 221

Metadata

Authors
Chouliaras, L., & O’Brien, J. T.
Affiliations
University of Cambridge (GB)
Venue
Molecular Psychiatry
Published
2023-08-22
Volume
28
Issue
10
Pages
4084-4097
ISSN
  • 1359-4184 (ISSN-L)
  • 1476-5578
OpenAlex
W4386050192
Cited by
221
References
258
Citations by year
2026: 81 · 2025: 105 · 2024: 33 · 2023: 2
FWCI
8.00
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Psychiatry (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Apollo (University of Cambridge) (submittedVersion, cc-by)
  • Apollo (cc-by)
Funders
  • National Institute for Health and Care Research ((NIHR203312, CL-2017-14-007)
  • Department of Health and Social Care
  • NIHR Cambridge Biomedical Research Centre (NIHR 203312)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Keywords
dementia, differential diagnosis, early diagnosis, Alzheimer's disease, vascular dementia, dementia with Lewy bodies, frontotemporal dementia, structural MRI, 18F-FDG PET, amyloid PET, tau PET, dopaminergic imaging, [11C]UCB-J, synaptic imaging, prodromal dementia, multimodal neuroimaging
MeSH terms
Alzheimer Disease, Diagnosis, Differential, Humans, Lewy Body Disease, Positron-Emission Tomography, Frontotemporal Dementia, Neuroimaging

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The use of neuroimaging techniques in the early and differential diagnosis of dementia. https://app.cochat.ai/papers/10.1038/s41380-023-02215-8
The paper
Chouliaras, L., & O’Brien, J. T. (2023). The use of neuroimaging techniques in the early and differential diagnosis of dementia. Molecular Psychiatry. https://doi.org/10.1038/s41380-023-02215-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.